Collegium Pharmaceutical, Inc. (COLL) Receives $20.17 Average Target Price from Brokerages

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have been assigned an average rating of “Buy” from the eight research firms that are presently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating and six have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $23.50.

Several equities research analysts have recently weighed in on the company. Piper Jaffray Companies reissued a “buy” rating and issued a $24.00 price target on shares of Collegium Pharmaceutical in a research note on Thursday. HC Wainwright assumed coverage on Collegium Pharmaceutical in a research note on Monday, September 11th. They issued a “buy” rating and a $21.00 price target for the company. Needham & Company LLC increased their price target on Collegium Pharmaceutical from $25.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday. They noted that the move was a valuation call. Jefferies Group increased their price target on Collegium Pharmaceutical to $27.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Zacks Investment Research raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Monday, August 14th.

In related news, CEO Michael Thomas Heffernan sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $15.53, for a total transaction of $776,500.00. Following the completion of the sale, the chief executive officer now owns 558,987 shares of the company’s stock, valued at $8,681,068.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CTO Alison B. Fleming sold 4,029 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $17.00, for a total value of $68,493.00. Following the sale, the chief technology officer now directly owns 28,513 shares of the company’s stock, valued at approximately $484,721. The disclosure for this sale can be found here. Insiders have sold 58,630 shares of company stock valued at $924,360 in the last ninety days. 25.76% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. American International Group Inc. grew its stake in Collegium Pharmaceutical by 27.8% during the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock worth $100,000 after purchasing an additional 2,163 shares during the period. Voya Investment Management LLC acquired a new stake in Collegium Pharmaceutical during the second quarter worth approximately $125,000. Credit Suisse AG grew its stake in Collegium Pharmaceutical by 9.4% during the first quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock worth $137,000 after purchasing an additional 1,173 shares during the period. UBS Group AG grew its stake in Collegium Pharmaceutical by 283.2% during the first quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock worth $139,000 after purchasing an additional 10,174 shares during the period. Finally, Nationwide Fund Advisors grew its stake in Collegium Pharmaceutical by 27.8% during the second quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock worth $161,000 after purchasing an additional 2,802 shares during the period. 79.98% of the stock is owned by institutional investors and hedge funds.

Shares of Collegium Pharmaceutical (COLL) traded up $1.13 during mid-day trading on Monday, hitting $18.34. The stock had a trading volume of 1,111,343 shares, compared to its average volume of 511,621. Collegium Pharmaceutical has a 12 month low of $7.37 and a 12 month high of $20.92.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.28. The company had revenue of $11.95 million during the quarter, compared to analysts’ expectations of $5.31 million. Collegium Pharmaceutical had a negative return on equity of 77.11% and a negative net margin of 447.83%. The business’s quarterly revenue was up 2814.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.13) earnings per share. sell-side analysts expect that Collegium Pharmaceutical will post -2.56 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.chaffeybreeze.com/2017/12/08/collegium-pharmaceutical-inc-coll-receives-20-17-average-target-price-from-brokerages.html.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply